Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Fed Circ sides with Axonics in patent validity battle
Pharma
US Court of Appeals highlights procedural rules in patent dispute concerning medical device charging patents | Medtronic now faces further patent validity reviews after Fed Circ rules in favour of rival.   8 August 2023
BMS and AstraZeneca settle dispute for $510m
Pharma
Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.   3 August 2023
Natera files patent lawsuit over DNA technology
Americas
The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.   1 August 2023
Americas
Polpharma’s injunction bid fails as motion is dismissed with prejudice | Court upholds Swiss Arbitration process.   20 July 2023
Biotech
Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.   18 July 2023
Pharma
Commission says dealmakers ‘knowingly and intentionally’ breached standstill obligation | Grail receives the first-ever fine for a target company under EU merger rules.   13 July 2023
Americas
John Rearick is the latest addition to the firm to strengthen its life sciences practice.   11 July 2023
article
The firm’s presence in Shenzhen will expand its focus on tech industries in the region.   5 July 2023
Pharma
Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.   4 July 2023
article
Lewis Silkin has integrated MSK into its practice to better manage complex portfolios across various tech sectors.   4 July 2023

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.